Amid what some would call chaos in the halls of the FDA, HHS, etc., some light came shining through recently. The FDA announced a new collaborative approach to a procedural pathway called Rare Disease Evidence Principles (RDEP) targeted at ultra-rare genetic diseases. Under RDEP, drugs and biologics that meet defined criteria may engage earlier with FDA’s review teams to pre-negotiate what evidence can support a “substantial evidence of effectiveness” determination. FDA is signaling that it will more explicitly consider nontraditional evidence (e.g., single-arm trials, external control arms, natural history studies).
Eligibility for the RDEP pathway is limited and sponsors must meet specific requirements:
- address a known inborn genetic defect whose dysfunction is a principal driver of disease;
- target a very small patient population (often < 1,000 in the U.S.);
- treat a disease with severe progressive deterioration (rapid disability or mortality);
- have no adequate alternative therapies; and
- directly correct or replace the defective gene or protein.
Once accepted, sponsors may benefit from a meeting with FDA to agree on required evidence and clarify what confirmatory or supportive data the agency will accept. However, post-marketing obligations may increase for products approved under RDEP.
For pharmaceutical manufacturers, key issues include:
- Strategic planning: early determination whether a therapy qualifies for RDEP and timing of the meeting request.
- Trial design flexibility: need to justify use of single-arm designs, external/natural history controls, or novel endpoints in lieu of large, randomized trials.
- Regulatory risk: despite flexibility in evidence considerations, the “substantial evidence” legal standard remains unchanged, so the burden of persuasion stays high.
- Post-approval commitments: increased post marketing study or monitoring obligations.
Opportunities include:
- Faster, more efficient development pathways, with earlier regulatory clarity.
- Reduced trial size and burden where patient recruitment is inherently constrained.
- Enhanced collaboration possibilities with FDA — sponsors can negotiate evidence expectations up front, reducing uncertainty.
- Differentiation and leadership in gene therapy / rare disease portfolio development, especially for biopharma firms with relevant platforms.
New FDA approval process promotes development of rare disease gene therapies
CLICK HERE to read the full analysis
